entinostat has been researched along with Hematologic Malignancies in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Entinostat is a well-tolerated HDACi that demonstrates promising therapeutic potential in both solid and hematologic malignancies." | 8.87 | Entinostat for treatment of solid tumors and hematologic malignancies. ( Gore, L; Knipstein, J, 2011) |
| "Entinostat is a well-tolerated HDACi that demonstrates promising therapeutic potential in both solid and hematologic malignancies." | 4.87 | Entinostat for treatment of solid tumors and hematologic malignancies. ( Gore, L; Knipstein, J, 2011) |
| "Therefore, in this review we focus upon hematologic malignancies." | 2.45 | Clinical studies of histone deacetylase inhibitors. ( Bishton, MJ; Harrison, SJ; Prince, HM, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prince, HM | 1 |
| Bishton, MJ | 1 |
| Harrison, SJ | 1 |
| Fandy, TE | 1 |
| Herman, JG | 1 |
| Kerns, P | 1 |
| Jiemjit, A | 1 |
| Sugar, EA | 1 |
| Choi, SH | 1 |
| Yang, AS | 1 |
| Aucott, T | 1 |
| Dauses, T | 1 |
| Odchimar-Reissig, R | 1 |
| Licht, J | 1 |
| McConnell, MJ | 1 |
| Nasrallah, C | 1 |
| Kim, MK | 1 |
| Zhang, W | 1 |
| Sun, Y | 1 |
| Murgo, A | 1 |
| Espinoza-Delgado, I | 1 |
| Oteiza, K | 1 |
| Owoeye, I | 1 |
| Silverman, LR | 1 |
| Gore, SD | 1 |
| Carraway, HE | 1 |
| Knipstein, J | 1 |
| Gore, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| A Dose-Finding Trial of the Histone Deacetylase Inhibitor MS-275 (NSC 706995) in Combination With 5-Azacitidine (5AC, NSC 102816) in Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMMoL) and Acute Myeloid Leukemia (AML)[NCT00101179] | Phase 1 | 63 participants (Actual) | Interventional | 2004-11-03 | Completed | ||
| High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)[NCT03217903] | 32 participants (Anticipated) | Interventional | 2017-10-12 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for entinostat and Hematologic Malignancies
| Article | Year |
|---|---|
Clinical studies of histone deacetylase inhibitors.
Topics: Antibiotics, Antineoplastic; Benzamides; Clinical Trials as Topic; Depsipeptides; Drug Therapy, Comb | 2009 |
Entinostat for treatment of solid tumors and hematologic malignancies.
Topics: Antineoplastic Agents; Benzamides; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans; Mo | 2011 |
1 trial available for entinostat and Hematologic Malignancies